Introduction to the EQIPD quality system
- PAASP, Germany
- Charité Universitätsmedizin, Germany
- Janssen Pharmaceutica NV, Belgium
- PAASP GmbH, Germany
- AAALAC International, Spain
- Porsolt, France
- Sanofi, France
- UCB, United Kingdom
- Novartis pharma, Switzerland
- Pfizer, United States
- University of Groningen, Netherlands
- Tel Aviv University, Israel
- Fraunhofer Institute for Molecular Biology and Applied Ecology IME, Germany
- Deutsches Zentrum für Neurodegenerative Erkrankungen e.V. (DZNE), Germany
- Charles River Laboratories, France
- Cohen Veterans Bioscience, United States
- German Mouse Clinic, Germany
- Helmholtz Zentrum München, Germany
- Broad Institute of MIT & Harvard, United States
- PAASP, France
- Polish Academy of Sciences, Poland
- Institute of Pharmacology, Toxicology, and Pharmacy, Germany
- National Council of Science and Technology, Mexico
- The University of Lausanne, Switzerland
- University of Aberdeen, United Kingdom
- Radboud University Medical Center, Netherlands
- University of Belgrade, Serbia
- Institute of Science and Technology, Austria
- University of Helsinki, Finland
- Imperial College London, United Kingdom
- Avertim, Belgium
- University of Edinburgh, United Kingdom
Abstract
While high risk of failure is an inherent part of developing innovative therapies, it can be reduced by adherence to evidence-based rigorous research practices. Numerous analyses conducted to date have clearly identified measures that need to be taken to improve research rigor. Supported through the European Union's Innovative Medicines Initiative, the EQIPD consortium has developed a novel preclinical research quality system that can be applied in both public and private sectors and is free for anyone to use. The EQIPD Quality System was designed to be suited to boost innovation by ensuring the generation of robust and reliable preclinical data while being lean, effective and not becoming a burden that could negatively impact the freedom to explore scientific questions. EQIPD defines research quality as the extent to which research data are fit for their intended use. Fitness, in this context, is defined by the stakeholders, who are the scientists directly involved in the research, but also their funders, sponsors, publishers, research tool manufacturers and collaboration partners such as peers in a multi-site research project. The essence of the EQIPD Quality System is the set of 18 core requirements that can be addressed flexibly, according to user-specific needs and following a user-defined trajectory. The EQIPD Quality System proposes guidance on expectations for quality-related measures, defines criteria for adequate processes (i.e., performance standards) and provides examples of how such measures can be developed and implemented. However, it does not prescribe any pre-determined solutions. EQIPD has also developed tools (for optional use) to support users in implementing the system and assessment services for those research units that successfully implement the quality system and seek formal accreditation. Building upon the feedback from users and continuous improvement, a sustainable EQIPD Quality System will ultimately serve the entire community of scientists conducting non-regulated preclinical research, by helping them generate reliable data that are fit for their intended use.
Data availability
We have not generated any data
Article and author information
Author details
Sandrine Bongiovanni
Esmeralda Castaños-Vélez
Alexander Dityatev
Ernesto Prado Montes de Oca
Funding
Innovative Medicines Initiative (777364)
- Malcolm R MacLeod
The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.
Reviewing Editor
- Mone Zaidi, Icahn School of Medicine at Mount Sinai, United States
Version history
- Received: September 21, 2020
- Accepted: May 20, 2021
- Accepted Manuscript published: May 24, 2021 (version 1)
- Version of Record published: June 7, 2021 (version 2)
Copyright
© 2021, Bespalov et al.
This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.
Metrics
-
- 3,226
- views
-
- 481
- downloads
-
- 35
- citations
Views, downloads and citations are aggregated across all versions of this paper published by eLife.
Download links
A two-part list of links to download the article, or parts of the article, in various formats.
Downloads (link to download the article as PDF)
Open citations (links to open the citations from this article in various online reference manager services)
Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)
Introduction to the EQIPD quality system
eLife 10:e63294.
https://doi.org/10.7554/eLife.63294
Further reading
-
- Neuroscience
Cortical folding is an important feature of primate brains that plays a crucial role in various cognitive and behavioral processes. Extensive research has revealed both similarities and differences in folding morphology and brain function among primates including macaque and human. The folding morphology is the basis of brain function, making cross-species studies on folding morphology important for understanding brain function and species evolution. However, prior studies on cross-species folding morphology mainly focused on partial regions of the cortex instead of the entire brain. Previously, our research defined a whole-brain landmark based on folding morphology: the gyral peak. It was found to exist stably across individuals and ages in both human and macaque brains. Shared and unique gyral peaks in human and macaque are identified in this study, and their similarities and differences in spatial distribution, anatomical morphology, and functional connectivity were also dicussed.
-
- Neuroscience
Complex skills like speech and dance are composed of ordered sequences of simpler elements, but the neuronal basis for the syntactic ordering of actions is poorly understood. Birdsong is a learned vocal behavior composed of syntactically ordered syllables, controlled in part by the songbird premotor nucleus HVC (proper name). Here, we test whether one of HVC’s recurrent inputs, mMAN (medial magnocellular nucleus of the anterior nidopallium), contributes to sequencing in adult male Bengalese finches (Lonchura striata domestica). Bengalese finch song includes several patterns: (1) chunks, comprising stereotyped syllable sequences; (2) branch points, where a given syllable can be followed probabilistically by multiple syllables; and (3) repeat phrases, where individual syllables are repeated variable numbers of times. We found that following bilateral lesions of mMAN, acoustic structure of syllables remained largely intact, but sequencing became more variable, as evidenced by ‘breaks’ in previously stereotyped chunks, increased uncertainty at branch points, and increased variability in repeat numbers. Our results show that mMAN contributes to the variable sequencing of vocal elements in Bengalese finch song and demonstrate the influence of recurrent projections to HVC. Furthermore, they highlight the utility of species with complex syntax in investigating neuronal control of ordered sequences.
